{"id":"NCT01715129","sponsor":"Ipsen","briefTitle":"Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer","officialTitle":"A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-10-26","resultsPosted":"2015-10-28","lastUpdate":"2019-12-09"},"enrollment":126,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Triptorelin Pamoate 11.25mg","otherNames":[]}],"arms":[{"label":"11.25mg","type":"EXPERIMENTAL"}],"summary":"Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.","primaryOutcome":{"measure":"Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183","timeFrame":"At Day 29 and 183","effectByArm":[{"arm":"Triptorelin Pamoate","deltaMin":97.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":12,"countries":["Bulgaria","France","Latvia","Poland","Romania"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":126},"commonTop":["Hot Flush","Weight Increased","Weight Decreased","Hypertension","Headache"]}}